Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.
HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.
VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.
HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.
In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.
As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its second quarter 2021 financial results on August 12, 2021, before market opening. The company focuses on developing novel immunotherapeutics using its proprietary arenavirus platform, with ongoing clinical trials for HPV 16-positive cancers and Cytomegalovirus. HOOKIPA aims to mobilize T cells and antibodies to combat serious diseases, with additional preclinical research in prostate cancer, HIV, and Hepatitis B in collaboration with Gilead Sciences.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced participation in upcoming virtual investor conferences, including the SVB Leerink CybeRx Series on June 21-22 and the JMP Securities Life Sciences Conference on June 16-17, featuring a fireside chat on June 17 at 10:00am ET. The live webcast will be available on HOOKIPA's website, with an archived replay for 30 days. HOOKIPA focuses on developing immunotherapies using its proprietary arenavirus platform, targeting oncology and infectious diseases, with ongoing clinical trials for Human Papilloma Virus and Cytomegalovirus.
HOOKIPA Pharma reported positive Phase 1 data for HB-200, a novel arenaviral therapeutic targeting HPV16+ cancers, at the 2021 ASCO Annual Meeting. The therapy demonstrated an average of 6% to 40% tumor-specific CD8+ T cell responses, supporting its potential efficacy. HB-201 monotherapy achieved an 18% overall response rate and a median progression-free survival of 3.45 months in heavily pretreated patients. The findings suggest that HOOKIPA's arenaviral platform could facilitate new cancer immunotherapy options. Further studies are planned for 2022.
HOOKIPA Pharma announced that the first data from their Phase 1 study on HB-201/HB-202, an arenaviral therapeutic for HPV16+ cancers, will be presented at the ASCO Annual Meeting from June 4-8, 2021. This includes safety, tolerability, and preliminary anti-tumor activity from 40 patients. The presentation highlights the potential of HOOKIPA's novel immunotherapeutics to enhance cancer treatment. Following the presentation, an investor event will provide insights into the trial's findings and HOOKIPA's future plans.
HOOKIPA Pharma reported encouraging preliminary Phase 1 data for its oncology candidates, HB-201 and HB-202, showing a robust antigen-specific CD8+ T cell response following one dose. The results align with prior pre-clinical studies, demonstrating an increase of up to 8% in antigen-specific circulating CD8+ T cells in patients with HPV16+ cancers. Financially, HOOKIPA posted revenues of $5.3 million for Q1 2021, up from $3.7 million in Q1 2020. However, net loss widened to $17.2 million, reflecting increased R&D expenses. The company is set to present further data at ASCO and other upcoming conferences.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is set to report its first quarter 2021 financial results on May 12, 2021. The company specializes in developing immunotherapeutics utilizing its proprietary arenavirus platform, which targets immune system activation. HOOKIPA's products include HB-201 and HB-202 for HPV-related cancers and HB-101, a vaccine for Cytomegalovirus in kidney transplant patients, both in clinical trials. HOOKIPA has also partnered with Gilead Sciences to explore HIV and Hepatitis B treatments.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in several upcoming virtual investor conferences. Key events include the 7th Annual Truist Securities Life Sciences Summit on May 4, the Bank of America Health Care Conference on May 13, the Morgan Stanley Asia Healthcare Conference on May 13-14, and the RBC Capital Markets Global Healthcare Conference on May 18. Live webcasts will be accessible on HOOKIPA's website, with replays available for 30 days. HOOKIPA is focused on developing innovative immunotherapeutics using its proprietary arenavirus platform.
HOOKIPA Pharma Inc. (NASDAQ: HOOK), a biopharmaceutical company focused on immunotherapeutics, announced its participation in the virtual Kempen Life Science Conference on April 21, 2021. The management team will host one-on-one meetings during the event. HOOKIPA is advancing a pipeline targeting virally mediated cancer antigens and infectious diseases, including its lead oncology candidates, HB-201 and HB-202, in Phase 1/2 trials. The company also collaborates with Gilead Sciences to explore functional cures for HIV and Hepatitis B infections, showcasing its innovative approach to immunotherapy.
HOOKIPA Pharma announced positive preliminary Phase 1 data for oncology candidates HB-201 and HB-202 targeting HPV16+ cancers. Key highlights include up to an 8% increase in circulating CD8+ T cells and significant immune activation, notably an increase in interferon-gamma. Presented at the AACR Annual Meeting, these results reinforce previous findings of anti-tumor activity. The ongoing Phase 1/2 study (NCT04180215) is exploring various dosing strategies with potential for major advancements in treatment options for metastatic HPV16+ cancers.
HOOKIPA Pharma reported a strong financial position with a cash balance of $143 million at year-end 2020, bolstered by a $80.9 million financing and collaboration revenue of $19.6 million from Gilead. The oncology candidate HB-201 demonstrated promising anti-tumor activity in HPV16+ cancers, while HB-101 showed effectiveness in reducing CMV viremia in kidney transplant patients. The company aims for additional clinical data in 2021, showcasing the potential of its proprietary arenavirus platform for immunotherapeutics.
FAQ
What is the current stock price of HOOKIPA Pharma (HOOK)?
What is the market cap of HOOKIPA Pharma (HOOK)?
What does HOOKIPA Pharma Inc. specialize in?
What are VaxWave® and TheraT®?
How do the arenavirus technologies work?
What recent achievements has HOOKIPA made?
How are HOOKIPA's viral vectors administered?
What is the financial condition of the company?
What is the significance of TheraT® in cancer treatment?
Who can be contacted for investor relations?
What are the upcoming projects for HOOKIPA?
What makes HOOKIPA's technologies unique?
